| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPT2 |
| Uniprot No | P23786 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-658aa |
| 氨基酸序列 | MVPRLLLRAW PRGPAVGPGA PSRPLSAGSG PGQYLQRSIV PTMHYQDSLP RLPIPKLEDT IRRYLSAQKP LLNDGQFRKT EQFCKSFENG IGKELHEQLV ALDKQNKHTS YISGPWFDMY LSARDSVVLN FNPFMAFNPD PKSEYNDQLT RATNMTVSAI RFLKTLRAGL LEPEVFHLNP AKSDTITFKR LIRFVPSSLS WYGAYLVNAY PLDMSQYFRL FNSTRLPKPS RDELFTDDKA RHLLVLRKGN FYIFDVLDQD GNIVSPSEIQ AHLKYILSDS SPAPEFPLAY LTSENRDIWA ELRQKLMSSG NEESLRKVDS AVFCLCLDDF PIKDLVHLSH NMLHGDGTNR WFDKSFNLII AKDGSTAVHF EHSWGDGVAV LRFFNEVFKD STQTPAVTPQ SQPATTDSTV TVQKLNFELT DALKTGITAA KEKFDATMKT LTIDCVQFQR GGKEFLKKQK LSPDAVAQLA FQMAFLRQYG QTVATYESCS TAAFKHGRTE TIRPASVYTK RCSEAFVREP SRHSAGELQQ MMVECSKYHG QLTKEAAMGQ GFDRHLFALR HLAAAKGIIL PELYLDPAYG QINHNVLSTS TLSSPAVNLG GFAPVVSDGF GVGYAVHDNW IGCNVSSYPG RNAREFLQCV EKALEDMFDA LEGKSIKS |
| 预测分子量 | 101 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CPT2重组蛋白相关的参考文献及其摘要概括：
1. **文献名称**: *"Expression and characterization of human carnitine palmitoyltransferase II in Escherichia coli"*
**作者**: B. J. Wu, P. A. Wood
**摘要**: 研究报道了在大肠杆菌中成功表达人源CPT2重组蛋白，并通过优化纯化条件获得高活性酶。实验表明重组CPT2对棕榈酰辅酶A具有特异性催化能力，为后续功能研究奠定基础。
2. **文献名称**: *"Functional analysis of mutant carnitine palmitoyltransferase II enzymes using a prokaryotic expression system"*
**作者**: F. M. Vaz, S. Denis, R. J. A. Wanders
**摘要**: 利用原核表达系统表达多种CPT2突变体，发现部分突变导致酶活性显著降低，揭示了CPT2缺陷症患者代谢异常的分子机制。
3. **文献名称**: *"Crystal structure of human mitochondrial carnitine palmitoyltransferase II"*
**作者**: A. M. Hisano, T. Nakagawa
**摘要**: 通过X射线晶体学首次解析了人源CPT2的三维结构，阐明了其底物结合域及催化机制，为针对脂肪酸代谢障碍的药物设计提供结构基础。
(注：以上文献为示例，实际引用时需核对原文信息。)
Carnitine palmitoyltransferase 2 (CPT2) is a mitochondrial enzyme critical for fatty acid β-oxidation, a key energy-generating process that converts fatty acids into acetyl-CoA. Located on the inner mitochondrial membrane, CPT2 catalyzes the conversion of acylcarnitines back to acyl-CoA esters, enabling their transport into the mitochondrial matrix for subsequent oxidation. This step is essential for maintaining energy homeostasis, particularly in tissues with high metabolic demands like skeletal muscle, heart, and liver.
CPT2 dysfunction is linked to autosomal recessive disorders characterized by impaired fatty acid oxidation. The most common form, CPT2 deficiency, manifests as life-threatening metabolic crises triggered by fasting, exercise, or infection. Symptoms range from hypoglycemia and myopathy to severe hepatic and cardiac complications. Research into CPT2 has been driven by the need to understand its structure-function relationships, mutation-induced pathologies, and therapeutic interventions.
Recombinant CPT2 protein is produced using heterologous expression systems (e.g., *E. coli*, mammalian cells) to study its biochemical properties and disease mechanisms. The recombinant protein retains enzymatic activity when properly folded, allowing *in vitro* assays to evaluate substrate kinetics, inhibitor sensitivity, and mutation impacts. Advanced purification techniques, including affinity chromatography and size-exclusion methods, ensure high-purity preparations for structural studies (e.g., X-ray crystallography) and drug discovery platforms.
Clinically, recombinant CPT2 serves as a tool for developing enzyme replacement therapies and personalized medicine approaches. It also aids in diagnostic assays to measure residual enzyme activity in patient samples. Recent efforts focus on stabilizing the protein for therapeutic use and identifying pharmacological chaperones to rescue mutant CPT2 folding. Ongoing research underscores its dual role as a metabolic regulator and a therapeutic target for rare lipid metabolism disorders.
×
